HomeFilePharmacology

Pharmacology

View Category

Other

ESC 2019 | DAPA-HF: Dapagliflozin Shows Benefit for All Subgroups

Dapagliflozin (a sodium glucose co-transporter 2 inhibitor), when indicated concomitantly with standard therapy, reduces significantly the...
solaci -
Learn More
Other

ESC 2019 | PARAGON-HF: Sacubitril/Valsartan Somewhat Disappointing, though a Few Would Benefit.

The combination Sacubitril/valsartan did not reduce the risk of rehospitalization for heart failure or cardiovascular death in...
solaci -
Learn More
Antiplatelet

ESC 2019 | THEMIS-PCI: Unlike in the Main Study, Here Ticagrelor Is Indeed Effective

This is a sub-study of the THEMIS presented during the ESC 2019 scientific sessions in Paris, and...
solaci -
Learn More
Antiplatelet

ESC 2019 | THEMIS: Ticagrelor in Diabetics with Stable Coronary Artery Disease

The use of ticagrelor in patients with stable coronary artery disease significantly reduces the rate of major...
solaci -
Learn More
Antiplatelet

ESC 2019 | POPULAR AGE: Good Old Clopidogrel Still Valid

According to this study, presented during the ESC 2019 scientific sessions, non-ST acute coronary syndrome (NSTE-ACS) patients...
solaci -
Learn More
Antithrombotic Anticoagulants

Do NOACs Result in Any Benefit in TAVR?

Courtesy of Dr. Carlos Fava. The need for anticoagulation after transcatheter aortic valve replacement (TAVR) is over 15%...
solaci -
Learn More
Other

Must Post MI Patients Use B Blockers for Life?

Long-term use of B blockers after myocardial infarction has been questioned for a while now; in fact,...
solaci -
Learn More
Other

Heart and Brain: Risk Factors, Atrial Fibrillation and Dementia

For decades, physiologists have known what cardiologists often forget: heart and brain communicate intensely in a healthy...
solaci -
Learn More